Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apogee Therapeutics Inc (APGE)

Apogee Therapeutics Inc (APGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,631,617
  • Shares Outstanding, K 68,320
  • Annual Sales, $ 0 K
  • Annual Income, $ -182,150 K
  • EBIT $ -283 M
  • EBITDA $ -295 M
  • 60-Month Beta 1.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.99

Options Overview Details

View History
  • Implied Volatility 55.07% (-4.36%)
  • Historical Volatility 31.61%
  • IV Percentile 5%
  • IV Rank 2.97%
  • IV High 236.20% on 06/20/25
  • IV Low 49.53% on 12/10/25
  • Expected Move (DTE 1) 3.77 (4.66%)
  • Put/Call Vol Ratio 0.63
  • Today's Volume 316
  • Volume Avg (30-Day) 559
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 11,644
  • Open Int (30-Day) 8,019
  • Expected Range 76.98 to 84.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.05
  • Number of Estimates 4
  • High Estimate -0.99
  • Low Estimate -1.16
  • Prior Year -1.19
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.56 +11.29%
on 01/05/26
84.56 -4.51%
on 01/14/26
+3.94 (+5.13%)
since 12/15/25
3-Month
51.80 +55.89%
on 10/23/25
84.56 -4.51%
on 01/14/26
+24.90 (+44.58%)
since 10/15/25
52-Week
26.20 +208.21%
on 04/08/25
84.56 -4.51%
on 01/14/26
+40.29 (+99.58%)
since 01/15/25

Most Recent Stories

More News
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression...

APGE : 80.75 (-2.04%)
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...

APGE : 80.75 (-2.04%)
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated...

APGE : 80.75 (-2.04%)
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential...

APGE : 80.75 (-2.04%)
Apogee Therapeutics to Participate in Upcoming Conferences

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences....

APGE : 80.75 (-2.04%)
Apogee Therapeutics Raises $323.3 Million in Offering

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Apogee Therapeutics...

APGE : 80.75 (-2.04%)
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...

APGE : 80.75 (-2.04%)
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...

APGE : 80.75 (-2.04%)
Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Apogee Therapeutics, with a price target of $89.00. The company’s shares closed yesterday at $39.61.Elevate Your...

APGE : 80.75 (-2.04%)
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for...

APGE : 80.75 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Apogee Therapeutics LLC is a biotechnology company advancing novel, potentially therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee Therapeutics LLC is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 85.30
2nd Resistance Point 84.31
1st Resistance Point 82.53
Last Price 80.75
1st Support Level 79.76
2nd Support Level 78.77
3rd Support Level 76.99

See More

52-Week High 84.56
Last Price 80.75
Fibonacci 61.8% 62.27
Fibonacci 50% 55.38
Fibonacci 38.2% 48.49
52-Week Low 26.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar